p14ARF expression in invasive breast cancers and ductal carcinoma in situ– relationships to p53 and Hdm2

Breast Cancer Research

Table 2 Immunohistochemical MQSs (0–8) for p14^ARF, p53 and Hdm2 expression in the nucleus and cytoplasm of invasive ductal cancer and ductal carcinoma in situ

Protein	Cancer type	Location	Tumour no. (%)	MQS 0–2 (0)	MQS 3–5 (1+)	MQS 6–8 (2+)
p14^ARF	Invasive	Nucleus	96	20 (21)	31 (32)	45 (47)
		Cytoplasm	95	72 (76)	16 (17)	7 (7)
	DCIS	Nucleus	91	17 (17)	29 (32)	45 (49)
		Cytoplasm	91	70 (80)	13 (14)	8 (9)
p53	Invasive	Nucleus	93	62 (67)	17 (18)	14 (15)
		Cytoplasm	93	70 (75)	18 (19)	5 (5)
	DCIS	Nucleus	91	66 (73)	12 (13)	13 (14)
		Cytoplasm	91	58 (62)	27 (29)	6 (6)
Hdm2	Invasive	Nucleus	92	49 (53)	33 (36)	10 (11)
		Cytoplasm	91	42 (46)	33 (36)	16 (18)
	DCIS	Nucleus	91	51 (56)	25 (27)	15 (16)
		Cytoplasm	91	43 (47)	27 (30)	21 (23)

Tumour numbers scored (MQS 0–8) by immunohistochemistry for p14^ARF, p53 and Hdm2 expression in the nucleus and cytoplasm of invasive cancers and ductal carcinoma in situ (DCIS) are shown. Immunohistochemistry expression was assessed individually in the nucleus and the cytoplasm, and is defined as negative (0) (MQS 0–2), weak/moderate (1+) (MQS 3–5) and strong (2+) (MQS 6–8). Positivity for p14^ARF, p53 and Hdm2 expression was defined as an MQS of 3 or more (1+/2+).

ISSN: 1465-542X